Simeprevir (Olysio) for the indication chronic hepatitis C

The therapeutic value of simeprevir in combination with pegIFN and ribavirin for the treatment of chronic hepatitis C genotype 1 and 4 is equal to that of sofosbuvir in combination with pegIFN and ribavirin, and for genotype 1 its therapeutic value exceeds that of telaprevir and boceprevir, both of which are given in combination with pegIFN and ribavirin.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.